HEC
EGRX

Hudson Executive Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hudson Executive Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-120,000
Closed -$4.86M – 12
2016
Q1 		$4.86M Buy
+120,000
New +$7.61M 1.12% 12

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hudson Executive Capital's EGRX Position: Q1 2020 in Review

Hudson Executive Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 661,897 shares — an estimated $39.8M sold.

Hudson Executive Capital first reported a position in EGRX in Q1 2016 and held it in 16 quarters. The position peaked at $78.8M in Q1 2017. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

  • Hudson Executive Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Hudson Executive Capital sold 661,897 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $39.8M.
  • Hudson Executive Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 16 quarters.
  • Hudson Executive Capital's Eagle Pharmaceuticals, Inc. position peaked at $78.8M in Q1 2017.
  • 168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on Hudson Executive Capital's 13F filing for Q1 2020, filed 15 May 2020.